Trial Design Optimization through the lens of Expected Net Present Value eNPV

  Рет қаралды 107

Berry Consultants

Berry Consultants

Күн бұрын

Пікірлер
Applying Bayeisan Optimisation to FACTS trial designs and choosing stopping bound
1:08:03
Applying Bayeisan Optimisation to FACTS trial designs and choosing stopping bound
Berry Consultants
Рет қаралды 50
Phase 2 Arm Dropping and RAR: Introduction to Adaptive Trial Designs using FACTS
1:28:46
Phase 2 Arm Dropping and RAR: Introduction to Adaptive Trial Designs using FACTS
Berry Consultants
Рет қаралды 214
coco在求救？ #小丑 #天使 #shorts
00:29
coco在求救？ #小丑 #天使 #shorts
好人小丑
Рет қаралды 120 МЛН
99.9% IMPOSSIBLE
00:24
99.9% IMPOSSIBLE
STORROR
Рет қаралды 31 МЛН
Қарғалардың анасы бар ма? | 1 серия | Сериал «‎QARGA 2»‎ | КОНКУРС
41:02
Қарғалардың анасы бар ма? | 1 серия | Сериал «‎QARGA 2»‎ | КОНКУРС
OMIR
Рет қаралды 1,4 МЛН
Une nouvelle voiture pour Noël 🥹
00:28
Une nouvelle voiture pour Noël 🥹
Nicocapone
Рет қаралды 9 МЛН
Phase 1 Dose Escalation: Introduction to Adaptive Trial Designs using FACTS
1:28:14
Phase 1 Dose Escalation: Introduction to Adaptive Trial Designs using FACTS
Berry Consultants
Рет қаралды 430
FACTS Case Study 5 A successful response adaptive dose finding phase 2 in Alzheimers
57:33
FACTS Case Study 5 A successful response adaptive dose finding phase 2 in Alzheimers
Berry Consultants
Рет қаралды 7
FACTS Case Study 2 A phase 3 adherence trial with unevenly spaced interims
48:11
FACTS Case Study 2 A phase 3 adherence trial with unevenly spaced interims
Berry Consultants
Рет қаралды 9
Group Sequential Designs: Introduction to Adaptive Trial Designs using FACTS
1:31:35
Group Sequential Designs: Introduction to Adaptive Trial Designs using FACTS
Berry Consultants
Рет қаралды 675
FACTS Case Study 4 A trial in haemorrhagic stroke wiht adaptive enrichment
1:03:28
FACTS Case Study 4 A trial in haemorrhagic stroke wiht adaptive enrichment
Berry Consultants
Рет қаралды 22
Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing
47:55
Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing
Invivoscribe
Рет қаралды 6
ACTA Masterclass: Industry Partnerships for Clinical Trial Networks
1:11:02
ACTA Masterclass: Industry Partnerships for Clinical Trial Networks
Australian Clinical Trials Alliance
Рет қаралды 586
FACTS Case Study 6 A 2 arm non inferiority study with borrowing from a previous study
1:04:12
FACTS Case Study 6 A 2 arm non inferiority study with borrowing from a previous study
Berry Consultants
Рет қаралды 8
FAIR for Machine Learning (FAIR4ML) IG: FAIR4ML IG Activity Updates and Feedback
1:01:59
FAIR for Machine Learning (FAIR4ML) IG: FAIR4ML IG Activity Updates and Feedback
RDA Research Data Alliance
Рет қаралды 7
Clinical Utility of NGS in Lymphoid Malignancies
59:21
Clinical Utility of NGS in Lymphoid Malignancies
Invivoscribe
Рет қаралды 22
coco在求救？ #小丑 #天使 #shorts
00:29
coco在求救？ #小丑 #天使 #shorts
好人小丑
Рет қаралды 120 МЛН